Aleafia Announces $13.0 Million Bought Deal Financing
Aleafia Health (TSX: ALEF) is the latest firm within the cannabis space to conduct a bought deal offering, announcing this morning that it would be conducting a $13.0 million financing. Eight Capital is the sole bookrunner on the capital raise.
The financing will see 20,000,000 units sold at a price of $0.65 per unit, with each unit consisting of one common share and one half warrant. Each warrant is valid for three years and contains an exercise price of $0.80 per common share. A 15% over-allotment option has also been granted that if exercised would bring the total value of the financing to $14.95 million.
Under the bought deal financing agreement, Aleafia Health has agreed to pay a cash fee to Eight Capital of 6.5%, in addition to providing compensation warrant coverage equal to 3.5% of the total units sold.
The financing is anticipated to close by May 29, with Aleafia indicating that it will use the funds for working capital and general corporate purposes.
Aleafia Health last traded at $0.76 on the TSX.
Information for this briefing was found via Sedar and Aleafia Health Inc. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.
